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Abstract 40 
The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a 41 
challenge, particularly in the case of close related entities like angio-immunoblastic T-42 
lymphomas (AITL) and PTCL-not otherwise specified (PTCL-NOS). Although gene 43 
expression profiling and next generations sequencing have been proven to define specific 44 
features recurrently associated with distinct entity, genomic-based stratifications have not 45 
yet led to definitive diagnostic criteria and/or entered into the routine clinical practice. 46 
Herein, to improve the current molecular classification between AITL and PTCL-47 
NOS, we analyzed the transcriptional profiles from 503 PTCLs stratified according to their 48 
molecular configuration and integrated them with genomic data of recurrently mutated genes 49 
(RHOAG17V , TET2, IDH2R172, and DNMT3A) in 53 cases (39 AITLs and 14 PTCL-NOSs) 50 
included in the series. Our analysis unraveled that the mutational status of RHOA, TET2 and 51 
DNMT3A poorly correlated, individually, with peculiar transcriptional fingerprint. Conversely, 52 
a strong transcriptional signature was identified in IDH2R172 samples. The integrated analysis 53 
of clinical, mutational and molecular data led to 19-genes model whose expression can more 54 
precisely differentiate the main PTCL nodal entities. According to the new proposed 55 
stratification, RHOAG17V,, TET2 and IDH2R217 mutations emerged as more robust diagnostic 56 
markers than previously reported for the differentiation between AITL and PTCL-NOS.  57 
This new gene classifier is simple and reproducible and able to improve the current 58 
molecular classification and diagnosis of PTCL. 59 
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Introduction 61 
Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of nodal and 62 
extra-nodal mature T-cell neoplasms accounting for approximately 10-15% of all lymphoma 63 
in the Western countries.1-5 The current WHO classification recognizes several distinct 64 
subsets, and multiple provisional entities have been recently proposed.3 The most frequent 65 
categories include PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic 66 
lymphoma (AITL), and anaplastic large T cell lymphoma (ALCL) with or without 67 
translocations involving ALK. 3 Overall, these entities encompass approximately 60% of all 68 
PTCL. With the exception of ALCL with ALK translocations, PTCL have an aggressive 69 
clinical course and poor response to conventional chemotherapy. Although new agents have 70 
been recently approved and several others are in clinical trials, the overall clinical success 71 
remains unsatisfactory.1,6-8 This is partially due to a limited knowledge of PTCL biology and 72 
reproducible/informative pre-clinical models, which have significantly hindered any 73 
mechanistic study aimed at testing candidate targeted treatments.  74 
Even though pathological diagnoses can be rendered in many patients, difficulties 75 
can occur, and in particular for those samples sharing features borderline between AITL and 76 
PTCL-NOS.9 Previous studies have shown that these two latter entities might bear distinct 77 
gene expression profiles (GEP).10-16 However, clinical usage of GEP has been limited due to 78 
its technical availability and to the absence of a consensus gene signature. Recent 79 
advances of next generation sequencing (NGS), and the discovery of recurrent mutated 80 
genes (RHOA, TET2, DNMT3A) in approximately 60-70% of AITL and in 20-30% of PTCL-81 
NOS, have somehow changed this landscape.15,17-20 Notably, 20-30% of AITLs cases can 82 
carry hotspot IDH2R172 mutations that are virtually absent in PTCL-NOSs.17 Nevertheless, 83 
these findings have not yet significantly impacted the clinical daily practice, which largely 84 
relies on histology and phenotype of tumor cells.3  Moreover, while some mutations appear 85 
to be linked to distinct GEP signature(s),15 the full potential of an integrated genotypic-86 
transcriptomic analysis has not been thoroughly tested.  87 
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Here, we collected a large GEP dataset of PTCL, and performed an integrative 88 
analysis with mutational data to improve the accuracy of disease classification, aiming of 89 
recognizing and more precisely stratifying AITL/PTCL-NOS lymphoma. 90 
 91 
Material and Methods 92 
We analysed 503 PTCL and 38 normal T-cell cases, univocally acquired from 8 93 
studies (GSE6338, GSE14879, GSE19067, GSE19069, GSE58445 and GSE65823 at 94 
http://www.ncbi.nlm.nih.gov/geo/; ETABM702 and ETABM783 at 95 
https://www.ebi.ac.uk/arrayexpress) (Supplementary Figure 1).10,12,21-24 Normalized data 96 
were extracted from CEL files using RMA procedure and the annotation for HG-U133Plus2.0 97 
arrays available at 98 
http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/21.0.0/entrezg.asp. 99 
A batch-effect correction was applied as previously described.25,26 The whole data set with 100 
all available clinical and genomic information acquired was uploaded to 101 
https://github.com/emacgene/PTCL. 102 
To investigate the contribution of recurrent mutations to the transcriptional pattern, 103 
we adapted a recently published analysis27 to 39 AITLs and 14 PTCL-NOSs for whom 104 
mutational data for IDH2R172, DNMT3A, TET2 and RHOA were available.15 Next, we created 105 
a model that included the lymphoma histotype, gene expression profile, genotype, and age 106 
and gender of each patient. Finally, ConsensusClusterPlus package for R 28 was used to 107 
determine the significance and robustness of natural grouping of patients based on selected 108 
transcriptional data, using Ward and Euclidean as linkage and distance metrics, 109 
respectively. CIBERSORT analysis was performed as previously described, using standard 110 
procedure and LM22 signature.29 Contingency analyses were performed by Fisher’s exact 111 
test (fisher.test R function). The CIBERSORT different contribution for each signature was 112 
then tested by pairwise.wilcox.test R function. Benjamini-Hochberg correction was used for 113 
multiple testing adjustment. The pathway enrichment analysis was performed using different 114 
modalities. First, the tmod R package was used on limma-derived signatures to decipher 115 
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whether clusters deregulate blood cell-associated transcriptional modules described by 116 
Chaussabel et al.30 and by Li et al.,31 according to the procedure described by Weiner et al.32 117 
The full analysis process written in R is provided in Supplementary Data 1. Second, gene 118 
set enrichment analysis was run on extended gene set modules using the GSEA java tool 119 
from the Broad institute (http://software.broadinstitute.org/gsea/index.jsp). In this second 120 
analysis, to reduce the incidence of false positives results, we choose the samr package, 121 
and a more conservative approach, to list differentially expressed genes. 122 
To validate our findings in an independent dataset, we imported data from 34 123 
previously published RNAseq samples (dbGap accession n. phs000689.v1.p1).17 The 124 
RNAseq raw expression data were normalized as previously described.33The full 125 
computational process written in R is provided in Supplementary Data 2. 126 
  127 
 6 
Results 128 
Dataset definition 129 
We analysed the transcriptional profiles of 503 PTCL cases and 38 normal donors 130 
provided by 8 different studies.10,12,13,21-24,34 According to the most recent updates in the T-131 
cell lymphoma molecular classification,3 these series included the following histotypes: 127 132 
AITL, 144 PTCL-NOS, 56 ALK+ ALCL, 96 ALK- ALCL, 21 Adult T-Cell Lymphoma (ATLL), 133 
59 NK/T-cell lymphomas (Figure 1a). By unsupervised hierarchical clustering and principal 134 
component analysis, ALK- and ALK+ ALCLs, ENKTL and ATLL were associated with distinct 135 
signatures; conversely, the transcriptional portrait of AITL and PTCL-NOS displayed a 136 
considerable overlap (Figure 1b-c). 137 
 138 
IDH2R172 but not RHOA, TET2 and DNMT3A is associated with specific transcriptional 139 
pattern 140 
To improve the distinction between AITL and PTCL-NOS, we integrated expression 141 
profiles with clinical, laboratory and mutational data (39 AITLs and 14 PTCL-NOSs) (See 142 
Material and Methods and Supplementary Data 1). This strategy lead to a preliminary list 143 
of 221/20.363 (1%) differentially modulated genes [false rate discovery (FDR) <1%] (Figure 144 
2a and Supplementary Table 1). Among these, 30 of them emerged as significantly and 145 
specifically associated to one distinct variable. Gender selectively impacted 14 genes 146 
located on the X and Y chromosome and for this reason they were not included for further 147 
analysis. Interestingly, the mutational status of RHOAG17V, TET2 and DNMT3A poorly 148 
correlated with any distinct transcriptional profile in both AITL and PTCL-NOS, as no gene 149 
showed differential expression to be correlated with the genotype (Figure 2b). Conversely, 150 
IDH2R172 samples were linked to a unique transcriptional signature including 3 genes with 151 
FDR <1%: ID2, NETO2 and SLC5A3 (Supplementary Data 1 and Figure 2b). Notably, 152 
AITL and PTCL-NOS transcriptional profiles could be differentiated by the expression of 13 153 
genes, including 3 of them recently described in recent gene expression model (ROBO1, 154 
ARHGEF10 and EFNB2) (Figure 2a-b).12  155 
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 Lastly, we decided to combine the signature specifically associated with IDH2R172 156 
mutational status (n=3) and those linked to histological diagnoses (n=13) to all AITL and 157 
PTCL-NOS (n=271) samples. This approach led to a hierarchical clustering with an 158 
improved clustering of PTCL-NOS and AITL cases. Collectively, these data are consistent 159 
with biologically distinct subgroups associated with specific mutational-based signatures, 160 
and linked to defined pathological features (Figure 2c). 161 
 162 
A 19-gene expression-based model distinguished PTCL subtypes 163 
Our group has previously described a 3-gene signature capable to effectively 164 
distinguish ALK- ALCLs from PTCL-NOS35. Here, we combined this 3-gene signature with 165 
our new 16-gene model, ultimately leading to a 19-gene model, aimed at improving the 166 
stratification of all major PTCL entities (ALK- ALCL, PTCL-NOS and AITL). This led to the 167 
recognition of five distinct subsets (Figure 3, Supplementary Data 1 and Table 1). The first 168 
group (C-1; n=87) was mainly composed by AITL samples (93%; 81/87), and enriched by 169 
IDH2R172 (16/36; 44%) and RHOAG17V(23/29; 79%) mutated lymphoma. The second (C-2; 170 
n=103), with an AITL-like signature, included samples annotated as well as PTCL-NOSs 171 
(64/103; 62%) and AITLs (33/103; 32%). In this group, IDH2R172 samples were minimally 172 
represented compared to C-1 (1/23; p=0.001); conversely, a higher prevalence of RHOA G17V 173 
mutations was observed (15/29; 52%); particularly higher than that seen in cluster 4 174 
(p=0.005). The third cluster represented only by 21 patients, included samples that could be 175 
linked to any of 3 main PTCL entities. Group 4 (C-4; n=63) included largely PTCL-NOSs 176 
(52/63; 82%), displaying a distinctive transcriptional profile characterized by a low 177 
prevalence of RHOA and TET2 mutations compared to C-1 (p<0.0001 and p=0.0002 178 
respectively) or C-2 (p=0.005 and 0.03 respectively) (Supplementary Figure 2).12 In the last 179 
cluster (C-5; n=55) ALK- ALCL cases (47/69; 68%) were over-represented, confirming the 180 
strong association between these lymphoma and the expression of TNFRSF8, BATF3 and 181 
TMOD1.35 No significant differences were observed in the DNMT3A mutational profile 182 
between any cluster (Table 1). Overall, this approach could improve the previous molecular 183 
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characterization of up to 8% AITLs, 31% ALK- ALCL and 29% PTCL-NOSs providing the 184 
bases of the recognition of unique biological subgroups (Table 1). 185 
Next, to discover potential gene classifiers, we investigated the global gene 186 
expression among samples within the 5 clusters (Supplementary Data 1). Firstly, we 187 
confirmed molecular signatures previously associated to AITL and PTCL-NOS (i.e ROBO1, 188 
LPAR1, SOX8, TUBB2B, TNFRSF8, TMOD1, BATF3, ATP6V0D1, CHI3L1, CREG1, CTSB, 189 
CTCS, FTL, HCK), strengthening the ability of the 19-gene model to differentiate distinct 190 
pathological entities.12,36 191 
Running 2 independent pathway analyses (Material and Methods and 192 
Supplementary Data 1), we observed a significant enrichment of B-cell and Plasma cell 193 
pathways among C-1 and C-2, in agreement with the notion that AITL are often enriched in 194 
B-cells/plasma cells; conversely the cluster 5 showed an enrichment for T-CD4 cell cycles 195 
pathway, but a significant low involvement of ITK/PKC and T-cell activation pathway 196 
(Supplementary Figure 3), in agreement with the consideration that the TCR signalling has 197 
been reported to be non-dominant in this group.37 198 
 199 
Validation Cohort 200 
To validate our 19-gene signature, we analyzed the RNAseq expression of 34 PTCL-201 
NOSs (11 AITL, 11 PTCL-NOS, 8 ALK- ALCL and 4 ALK+ ALCL) from a previously 202 
published dataset.17 The expression data of 2 of 19 genes were not available (AL441992.1 203 
and SLC5A3). Using the remaining 17 genes we were able to extract 4 main clusters 204 
(Supplementary Data 2 and Figure 4). The first cluster was compatible with the C-1 and C-205 
2 (AITL and AITL-like) clusters. All RHOA, TET2 and IDH2R172 mutated cases were included 206 
in this cluster mostly composed by a fraction of PTCL-NOSs (6/11) and all AITLs (10/10). 207 
The second was characterized by a profile similar to the C-4 group, with PTCL-NOS without 208 
RHOA and TET2 mutations. The remaining clusters included the great majority of ALK+ and 209 
ALK- ALCL cases (9/11).  210 
 211 
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Computational investigation defines distinct tumor-host compositions  212 
Seeking to discover whether the new PTCL clusters may be linked/associated to any 213 
host-tumor features, we used CIBERSORT to define the cellular composition of the tumor 214 
and host elements. CIBERSORT is a computational tool that accurately resolves relative 215 
fractions of different elements within complex environments (Figure 5a and Supplementary 216 
Data 1).29 This analysis revealed that the C-1 and C-2 clusters were characterized by a 217 
highest contribution of plasma cell and B-cell signatures (Figure 5b). Conversely, both 218 
clusters displayed a very low T-reg but high macrophages M0 signals. Cluster 5, mainly 219 
represented by ALK- ALCLs, was enriched for activated T-cell CD4+ and by Macrophages 220 
(M1 and M2) signatures (Figure 5b and Supplementary Data 1). Notably, the contribution of 221 
T-follicular helper cells was significantly lower in C5 than in the C-1, C-2 and C-4 groups. 222 
Lastly, the C-3 cluster was characterized by a unique profile associated with NK-cell 223 
(p<0.01) and activated mast cell (p<0.001) signatures, likely reflecting unique features of 224 
these lymphoma compared to those seen on bona fide AITL, PTCL-NOS and ALCL cases 225 
(Supplementary Data 1). 226 
  227 
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Discussion 228 
GEP has emerged as one of the most robust and reliable approach to differentiate 229 
human lymphoma. This has also been true for T-cell lymphoma, a strategy that have allowed 230 
the identification of even closely related entities like AITL and PTCL-NOS. 10,12,22-24,34,35 231 
However, GEP profile from formalin fixed paraffin embedded samples has been technical 232 
problematic and thus the molecular/expression stratification of PTCL has not entered yet into 233 
the routine clinical practice. Recently, novel technologies (e.g. NanoString) have provided for 234 
the first time a reproducible and feasible quantification of specific transcripts, mainly for 235 
diffuse large B-cell lymphoma.38-40 conversely, this approach has not yet been tested in 236 
PTCL, likely because a short and robust list of differentially expressed genes has not 237 
emerged yet.  238 
To bridge this gap, we performed meta-analysis of the largest PTCL series collected 239 
to date to assess the molecular profile of the main PTCL subgroups and define a usable list 240 
of significant differentially expressed genes. By integrating NGS and GEP data, we were 241 
able to discover the transcriptional impact of the recurrent mutations of AITLs and PTCL-242 
NOSs. Indeed, we found that TET2, DNMT3A, RHOAG17V  mutations did not show any 243 
distinct gene expression signatures. This last mutation was detected at sub-clonal level in a 244 
significant fraction of these cases and this may explain its low impact on transcriptional 245 
configuration. 15 TET2 and DNMT3A mutations are likely as early as hematopoietic stem 246 
cells mutations involved in clonal hemopoiesis;,41,42 therefore, we could not exclude that 247 
TET2-associated gene expression signature might be shared by other subtypes and masked 248 
by AITL molecular classification, subsequently limiting its extraction through our statistical 249 
process. Conversely, in line with a previous report,15 the IDH2R172 mutation significantly 250 
correlated with a distinct expression signature independent from the molecular subgroup. By 251 
integrating pathology, NGS and GEP analyses we defined a short list of highly predictive 252 
genes (n=19) whose differential expression divided the samples into 5 clusters, strongly 253 
associated with distinct PTCL entities. Specifically, C-1 and C-2 were characterized by most 254 
of the AITL hallmarks. In addition, despite their limited gene expression impact, the great 255 
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majority of RHOA G17V and TET2 mutations were grouped together, confirming their potential 256 
utility in the diagnostic process of these lymphoma. A significant fraction of PTCL-NOS were 257 
included in these 2 AITL clusters sharing high prevalence of RHOA and TET2 mutations and 258 
expressing some distinct, and in part previously reported, AITL-associated genes, 259 
suggesting a better ability of this model to re-assign more correctly the T-follicular helper 260 
PTCLs. 261 
 Furthermore, even without a direct GEP impact, RHOA mutations were mostly 262 
clustered within AITL clusters, emerging together with IDH2R217 mutations as a potential 263 
specific diagnostic marker to be further employed in routine diagnostics. Lastly, The majority 264 
of PTCL-NOS not assigned to C-2, composed a unique and distinct cluster (C4). 265 
Based both on the present and recently published10,12,37 data, PTCL-NOS group 266 
within the C-4 could not be considered any more like an “orphan” or “not-otherwise 267 
specified” subset, but instead as a distinct biologically entity. In fact, the lymphoma patients 268 
within this cluster have a distinct genotypic and transcriptomic pattern, mostly characterized 269 
by a significant enrichment in downregulated genes, confirming previous findings.13 Clearly, 270 
further studies will be needed to confirm our findings, and to further refine the list of genomic 271 
driver events and genes whose expression levels may have diagnostic value. However, our 272 
data were preliminarily cross-validated in an independent small RNAseq cohort17, confirming 273 
the robustness of the signature. This was true even across gene expression platforms, and 274 
thus represents a promising test bed for future routine nanostring approaches.  275 
Combining the expression levels and the mutational status of a limited set of genes 276 
in future studies, we will be able to improve the current diagnostic approach of PTCLs and 277 
lay the basis for effective treatments through the identification of recurrently dysregulated 278 
pathways. 279 
  280 
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Figure Legends: 295 
Figure 1. a) Molecular composition of the gene expression cohort (541 cases). 296 
Unsupervised hierarchical clustering (b) and PCA analysis (c) on the entire series.  297 
 298 
Figure 2. a) Distribution of the variance of expression levels across genes explained by 299 
clinical, molecular and genetic alterations (f-test; FDR<1%; n=221). b) Statistically significant 300 
mutation expression interaction terms (f-test; FDR<1%), for each alteration and clinical 301 
variable. The associated logarithmic expression fold change is indicated by colour. c) 302 
Hierarchical clustering of 271 PTCL-NOSs and AITLs based on the 16-signfiicantly extracted 303 
genes. The mutational status for TET2, RHOA, DNMT3A, IDH2R172 was reported on the top. 304 
 305 
Figure 3. Heatmap of the 19-genes model including all PTCL-NOS, AITL and ALK- ALCL 306 
cases (n=367), stratified according to the cluster determined by the ConsensusClusterPlus R 307 
function. 308 
 309 
Figure 4. a) CIBERSORT profile of each enrolled tumour sample (n=503). b) Boxplot of the 310 
relative estimated percentage for the most relevant and significant cell types, stratified by 311 
groups (Wilcoxon rank sum test for comparisons). 312 
 313 
Figure 5. Validation of the 19-gene model on a RNAseq external series.  314 
 315 
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Supplementary Figure Legend 317 
 318 
Supplementary Figure 1. Summary of the histological composition of each external gene 319 
expression data set included in this study. 320 
 321 
Supplementary Figure 2. Heat map based on the differential expression of the 16-genes 322 
between the C-2 and C-4 PTCL-NOSs. 323 
 324 
Supplementary Figure 3. The tmod most significant differentially enriched pathway among 325 
the extracted 5 clusters,  326 
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